Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Rising Doses of Doramapimod in Healthy Volunteers
NCT02208856Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 1999
- Primary completion
- Dec 1999
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of doramapimod in Crohn's disease, rheumatoid arthritis (RA) and psoriasis (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of subjects with clinically relevant changes in vital signs up to 96 hours, Number of subjects with clinically relevant changes in laboratory measurements up to 96 hours and 2 more. Started Sep 1999; status: completed.
02
Drugs
doramapimod
03
Conditions
Crohn's diseaserheumatoid arthritis (RA)psoriasis
Beyond the preview
Go deeper on NCT02208856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02208856.